<DOC>
	<DOCNO>NCT00578760</DOCNO>
	<brief_summary>Aspirin ( ASA ) show , animal model , attenuate ototoxic property cisplatin . The researcher plan investigate patient undergo cisplatin chemotherapy . The researcher hypothesise low-dose aspirin prevent cisplatin induced ototoxicity clinical setting .</brief_summary>
	<brief_title>Does Aspirin Have Protective Role Against Chemotherapeutically Induced Ototoxicity ?</brief_title>
	<detailed_description>Cisplatin high ototoxic potential platinum contain compound . It use treatment squamous cell carcinoma head neck , germ cell tumours testis bladder carcinoma . 42 % 400 patient receive high-dose cisplatin ( 70-85 mg/m2 , median cumulative dose 420mg ) experience common toxicity criterion ( CTC : appendix 1 ) grade 3 4 symptom ( De Jongh 2003 ) . Ototoxicity dose related : 75-100 % patient receive high dose 20-40 % low dose regime develop significant ototoxic symptom . In one study , 50 % head neck cancer patient treat cisplatin develop ototoxicity ( Blakley 1994 ) . Cisplatin ototoxicity present variable collection symptom sign . These include bilateral symmetrical hearing loss permanent irreversible . High frequency sensorineural hearing loss progression towards low frequency . Tinnitus , also permanent irreversible . There number know factor predispose cisplatin ototoxicity . They include : Dose , duration mode administration , age extreme , previous concurrent cranial irradiation , previous history hearing loss , renal disease , concomitant use ototoxic drug , noise exposure concomitant cisplatin administration , decrease serum albumin level , low hemoglobin level , low red blood cell count low haematocrit . Interestingly , cisplatin ototoxicity consider exclusively confine cochlear , vestibular system unaffected ( Myers 1993 ) . Ototoxicity chemotherapeutic agent due , part , reactive oxygen specie . Reactive oxygen specie attenuate antioxidant . Salicylates antioxidant administer aspirin . It show , animal model , aspirin protect hear cisplatin induced ototoxicity ( Li 2002 ) . In set experiment , rat use evaluate protective role aspirin acute chronic setting . Auditory evoke brain stem response use determine pre- post-intervention hearing threshold . In acute experiment ( n=23 ) , one dose cisplatin ( 16mg/kg ) administer animal give aspirin ( 100mg/kg ) start day cisplatin treatment continue 4 day thereafter . There significant difference hearing threshold treatment control group 3 , 8 14kHz . In chronic experiment cisplatin give day 1 , 4 7 ( 5mg/kg ) . Aspirin give 2 day 3 day cisplatin treatment ( 100mg/kg bd ) . The hearing threshold compare first dose 10 day last treatment . In animal treat concurrently aspirin , hear differ form control animals 16 24 kHz . This correlated significant reduction inner hair cell loss 20 % ( cisplatin ) 8 % ( cisplatin aspirin ) . Salicylates also protect renal function determine plasma blood urea nitrogen creatinine level . Salicylates affect tumour mass metastasis . The rat inoculate malignant breast cancer cell ( metastatic mammary adenocarcinoma ) . Aspirin protect cisplatin-induced ototoxicity , without affect oncolytic action cisplatin . Gentamicin cisplatin similar ototoxic mechanism action . Aspirin show prevent gentamicin-induced hearing loss without compromise anti-bacterial efficacy animal model clinical setting ( Sha 2006 , Chen 2007 ) . Sha 's group report prospective , randomize , double-blind trial 200 patient . The patient require gentamycin clinical indication . In 'treatment ' arm study , patient also receive aspirin ( 1g tds 14 day ) . A significant difference hear show 6 8kHz &gt; 15dB aspirin give .</detailed_description>
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Patients undergo cisplatin treatment follow malignancy : germcell bladder head neck ( Only head neck patient require 2 cycle postoperative chemoradiotherapy , therefore require gastrostomy tube , enrol . ) Over 18 year age Normal otoscopic examination Informed consent Patients follow exclude : Not able grasp study implication unable consent . History peptic ulcer disease Severe renal impairment ( U &amp; E , Cr clearance ) Haemophilia Severe hepatic impairment Cerebrovascular haemorrhage Acute gout Hypersensitivity NSAIDs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>hearing loss</keyword>
	<keyword>ototoxicity</keyword>
	<keyword>cisplatin</keyword>
</DOC>